GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (FRA:ASZ1) » Definitions » Short Percentage of Float

Alimera Sciences (FRA:ASZ1) Short Percentage of Float


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Alimera Sciences's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alimera Sciences's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Alimera Sciences's Short Percentage of Float falls into.


Alimera Sciences (FRA:ASZ1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (FRA:ASZ1) » Definitions » Short Percentage of Float
Comparable Companies
ZOM LFCR TKNO OPTN ELTP RGC AQST EBS ESPR ETON ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
ALIM:USA
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Website
https://www.alimerasciences.com
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (FRA:ASZ1) Headlines

No Headlines